Streetbeat News

Price Targets

ED

Barclays analyst Eric Beaumont has maintained an Equal-Weight rating on Consolidated Edison (NYSE:ED) but reduced the price target from $88 to $86.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:29 pm

CPSI

Barclays analyst Stephanie Davis has maintained an Equal-Weight rating on CPSI (NASDAQ:CPSI) but has reduced the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:27 pm

XNCR

Mizuho analyst Mara Goldstein has maintained a Buy rating on Xencor (NASDAQ:XNCR) but reduced the price target from $59 to $50.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:25 pm

SR

Mizuho analyst Gabriel Moreen has maintained a Buy rating on Spire Inc. (NYSE:SR) but has reduced the price target from $66 to $64.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:23 pm

CYTK

Mizuho analyst Salim Syed has reaffirmed a Buy rating on Cytokinetics (NASDAQ:CYTK) and increased the price target from $80 to $103, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:17 pm

ADMA

Mizuho analyst Anthony Petrone has reaffirmed a Buy rating on ADMA Biologics (NASDAQ:ADMA) and increased the price target from $7 to $9, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:15 pm

CART

Benchmark analyst Mark Zgutowicz has initiated coverage on Maplebear, trading under the ticker CART on NASDAQ, with a Buy rating and a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:09 pm

COMS

ThinkEquity analyst Ashok Kumar has initiated coverage on ComSovereign Holding (NASDAQ:COMS) with a Buy rating and set a price target of $3 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:03 pm

CNP

Barclays analyst Eric Beaumont has maintained an Underweight rating on CenterPoint Energy (NYSE:CNP) but increased the price target from $27 to $28.

Portfolio Pulse from Benzinga Newsdesk

January 22, 2024 | 2:02 pm

EYPT

EyePoint Pharmaceuticals (NASDAQ:EYPT) has been evaluated by 7 analysts over the last three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $31.71, up 18.54% from the previous $26.75, with a high estimate of $44.00 and a low of $20.00. Recent analyst actions include ratings and price target adjustments by JP Morgan, HC Wainwright & Co., Capital One, and Mizuho. EyePoint Pharmaceuticals focuses on ophthalmic products and has shown a revenue growth of 51.84% as of September 30, 2023. However, it has a net margin of -82.96% and an ROE of -21.77%, indicating profitability challenges.

Portfolio Pulse from Benzinga Insights

January 22, 2024 | 2:01 pm